Cara Therapeutics, Inc.
Compare this stock
CARA Stock Report Card
$
32%
Performance
Score:
10/100
CARA returned -89.02% in the last 12 months. Based on SPY's performance of -20.58%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
79/100
7 analysts offer 12-month price targets for CARA. Together, they have an average target of 28, the most optimistic target put CARA at 30 within 12-months and the most pessimistic has CARA at 26.
Sentiment
Score:
67/100
CARA had a bullish sentiment score of 67.18% across Twitter and StockTwits over the last 12 months. It had an average of 7.42 posts, 3.60 comments, and 9.03 likes per day.
Technicals
Score:
14/100
CARA receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
Score:
10/100
CARA has missed earnings 6 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, CARA has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
41/100
CARA has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
Cara Therapeutics, Inc. Summary
Nasdaq / CARA
Healthcare
Biotechnology
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
CARA scored poorly on our reportcard. Here are some similar companies and how they performed.
